ImmuCell Corporation

9.72-0.0300-0.31%Vol 3.36K1Y Perf 132.10%
Apr 9th, 2021 14:06 DELAYED
BID9.50 ASK9.75
Open9.63 Previous Close9.75
Pre-Market- After-Market-
 - -  - -%
Target Price
14.00 
Analyst Rating
— — 0.00
Potential %
44.03 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     59.17
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     58.86
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap70.19M 
Earnings Rating
Neutral
Price Range Ratio 52W %
62.98 
Earnings Date
12th May 2021

Today's Price Range

9.609.72

52W Range

3.8013.20

5 Year PE Ratio Range

-159.5072.40

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Buy
Performance
1 Week
-1.82%
1 Month
-7.87%
3 Months
56.02%
6 Months
70.68%
1 Year
132.10%
3 Years
31.35%
5 Years
49.54%
10 Years
194.19%

TickerPriceChg.Chg.%
ICCC9.72-0.0300-0.31
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
4.40
5.50
0.26
0.38
-1.50
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
44.70
-4.00
11.30
-3.50
-8.95
RevenueValueIndustryS&P 500US Markets
10.43M
1.44
17.08
9.65
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.03-
Q03 2020--0.04-
Q02 2020--0.11-
Q01 2020--0.02-
Q04 2019--0.06-
Q03 2019--0.07-
Q02 2019--0.09-
Q01 2019-0.03-
Earnings Per EndEstimateRevision %Trend
12/2021 FY-0.110.00-
12/2021 FY-0.1154.17Positive
----
----
Next Report Date12th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume3.36K
Shares Outstanding7.22M
Trades Count65
Dollar Volume440.92K
Avg. Volume48.68K
Avg. Weekly Volume6.67K
Avg. Monthly Volume13.76K
Avg. Quarterly Volume51.31K

ImmuCell Corporation (NASDAQ: ICCC) stock closed at 9.72 per share at the end of the most recent trading day (a -0.31% change compared to the prior day closing price) with a volume of 3.36K shares and market capitalization of 70.19M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 57 people. ImmuCell Corporation CEO is Micheal F. Brigham.

The one-year performance of ImmuCell Corporation stock is 132.1%, while year-to-date (YTD) performance is 63.36%. ICCC stock has a five-year performance of 49.54%. Its 52-week range is between 3.8 and 13.2, which gives ICCC stock a 52-week price range ratio of 62.98%

ImmuCell Corporation currently has a PE ratio of -68.90, a price-to-book (PB) ratio of 2.46, a price-to-sale (PS) ratio of 6.71, a price to cashflow ratio of 52.90, a PEG ratio of 2.32, a ROA of -2.48%, a ROC of -2.54% and a ROE of -3.42%. The company’s profit margin is -8.95%, its EBITDA margin is 11.30%, and its revenue ttm is $10.43 Million , which makes it $1.44 revenue per share.

Of the last four earnings reports from ImmuCell Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. ImmuCell Corporation’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for ImmuCell Corporation is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for ImmuCell Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ImmuCell Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ImmuCell Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.68, ATR14 : 0.97, CCI20 : -133.25, Chaikin Money Flow : -0.31, MACD : 0.13, Money Flow Index : 30.98, ROC : -17.63, RSI : 47.54, STOCH (14,3) : 28.70, STOCH RSI : 0.28, UO : 36.84, Williams %R : -71.30), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ImmuCell Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies.

CEO: Micheal F. Brigham

Telephone: +1 207 878-2770

Address: 56 Evergreen Drive, Portland 04103, ME, US

Number of employees: 57

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

52%48%

Bearish Bullish

50%50%

News

Stocktwits